JP2020515644A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515644A5
JP2020515644A5 JP2020503100A JP2020503100A JP2020515644A5 JP 2020515644 A5 JP2020515644 A5 JP 2020515644A5 JP 2020503100 A JP2020503100 A JP 2020503100A JP 2020503100 A JP2020503100 A JP 2020503100A JP 2020515644 A5 JP2020515644 A5 JP 2020515644A5
Authority
JP
Japan
Prior art keywords
ifn
mrna
utr
residues
systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020503100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515644A (ja
JP7264867B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/058036 external-priority patent/WO2018178215A1/en
Publication of JP2020515644A publication Critical patent/JP2020515644A/ja
Publication of JP2020515644A5 publication Critical patent/JP2020515644A5/ja
Application granted granted Critical
Publication of JP7264867B2 publication Critical patent/JP7264867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020503100A 2017-03-31 2018-03-29 非メラノーマ皮膚癌(nmsc)の予防および治療 Active JP7264867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162.0 2017-11-06
EP17200162 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (3)

Publication Number Publication Date
JP2020515644A JP2020515644A (ja) 2020-05-28
JP2020515644A5 true JP2020515644A5 (cg-RX-API-DMAC7.html) 2021-04-15
JP7264867B2 JP7264867B2 (ja) 2023-04-25

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503100A Active JP7264867B2 (ja) 2017-03-31 2018-03-29 非メラノーマ皮膚癌(nmsc)の予防および治療

Country Status (8)

Country Link
US (1) US20200038487A1 (cg-RX-API-DMAC7.html)
EP (2) EP4019037A1 (cg-RX-API-DMAC7.html)
JP (1) JP7264867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190133216A (cg-RX-API-DMAC7.html)
CN (1) CN110636854A (cg-RX-API-DMAC7.html)
AU (1) AU2018246292A1 (cg-RX-API-DMAC7.html)
CA (1) CA3057768A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018178215A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
US11518784B2 (en) 2019-05-08 2022-12-06 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
WO1990000406A1 (en) 1988-07-05 1990-01-25 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
IL129387A0 (en) 1996-10-18 2000-02-17 Canji Inc Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CA2323604A1 (en) 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Similar Documents

Publication Publication Date Title
JP2020529208A5 (cg-RX-API-DMAC7.html)
Zeng et al. Formulation and delivery technologies for mRNA vaccines
JP2018516983A5 (cg-RX-API-DMAC7.html)
ES2340499T3 (es) Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
FI4017871T3 (fi) Alfa-sarkoglykaaniin liittyvä adeno-assosioidun virusvektorin antaminen ja lihasdystrofian hoito
KR102432434B1 (ko) Rna 투여용 제형
JP2023519173A5 (cg-RX-API-DMAC7.html)
Neshat et al. Gene delivery for immunoengineering
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
KR100817024B1 (ko) 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
ES2963179T3 (es) Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas
Sällberg et al. Electroporation for therapeutic DNA vaccination in patients
WO2010142017A1 (en) Administration of interferon for prophylaxis against or treatment of pathogenic infection
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
ES2682056B1 (es) Material hibrido poroso organico - inorganico, metodo de obtencion y usos
JP2015513897A5 (cg-RX-API-DMAC7.html)
Yihunie et al. Recent advances in messenger ribonucleic acid (mRNA) vaccines and their delivery systems: a review
JP2017507703A (ja) カニューレ、注射または注入装置、およびカニューレまたは注射もしくは注入装置を使用する方法
JP5439189B2 (ja) 組換えヒトインターフェロン様タンパク質及びそれをエンコードするポリヌクレオチド
EA201100809A1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR20190133216A (ko) 비흑색종 피부암(nmsc)의 예방 및 치료
Copur Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
Tevz et al. Controlled systemic release of interleukin‐12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas
JP2021500880A5 (cg-RX-API-DMAC7.html)
ZA202304877B (en) Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof